HIGHLIGHTS
- who: Attilio Guarini and colleagues from the Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy have published the paper: Safety and Efficacy of Subcutaneous Rituximab in Previously UntreatedPatientswithCD20 + DiffuseLargeB-CellLymphomaor Follicular Lymphoma: Results from an Italian Phase IIIb Study, in the Journal: Advances in Hematology of 27/01/2022
- what: Although the design of this study was mainly descriptive and was not aimed at comparing the two DLBCL and FL subgroups, erythema (i.e., the most common ARR in both the Italian and Spanish studies) was reported in more . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.